Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

Beware the increasing cost and number of orphan drugs.

Silverman E.

Manag Care. 2013 Mar;22(3):10-4. No abstract available.

2.

How to swallow prescription prices.

Podolsky D.

US News World Rep. 1991 Oct 7;111(15):96. No abstract available.

PMID:
10115682
3.

Regulators adopt more orphan drugs.

Reardon S.

Nature. 2014 Apr 3;508(7494):16-7. doi: 10.1038/508016a. No abstract available.

PMID:
24695293
4.

Pricing pain: relief in sight on drug costs?

[No authors listed]

J Am Health Policy. 1992 Nov-Dec;2(6):28-31.

PMID:
10122415
5.
6.

The prevalence and cost of unapproved uses of top-selling orphan drugs.

Kesselheim AS, Myers JA, Solomon DH, Winkelmayer WC, Levin R, Avorn J.

PLoS One. 2012;7(2):e31894. doi: 10.1371/journal.pone.0031894. Epub 2012 Feb 21.

7.

Orphan drugs.

Novack GD.

Ocul Surf. 2008 Jan;6(1):52-3. No abstract available.

PMID:
18264655
8.

Duel over discounts. Pharma, providers at odds over 'orphan drugs'.

Daly R.

Mod Healthc. 2012 Jan 23;42(4):30-1. No abstract available.

PMID:
22359763
9.

The Orphan Drug Act: an engine of innovation? At what cost?

Rohde DD.

Food Drug Law J. 2000;55(1):125-43. No abstract available.

PMID:
12322720
10.

[Orphan drugs: drugs for rare diseases].

Schenk M.

Dtsch Med Wochenschr. 2010 May;135(18):p17. German. No abstract available.

PMID:
20455291
11.

Adoption agents.

Wapner J.

Sci Am. 2010 Jun;302(6):19-20. No abstract available.

PMID:
20521471
12.

[Orphan drugs: some legal, ethical and economics aspects].

Pabst JY.

Rev Epidemiol Sante Publique. 2001 Sep;49(4):387-96. French.

PMID:
11567205
13.

Pricing and reimbursement of orphan drugs: the need for more transparency.

Simoens S.

Orphanet J Rare Dis. 2011 Jun 17;6:42. doi: 10.1186/1750-1172-6-42.

14.

Dutch doctors call for EU evaluation of cost effectiveness of high cost orphan drugs.

Sheldon T.

BMJ. 2012 Aug 13;345:e5461. doi: 10.1136/bmj.e5461. No abstract available.

PMID:
22890124
15.

Getting to the Root of High Prescription Drug Prices.

Waxman H, Corr B, Martin K, Duong S.

Issue Brief (Commonw Fund). 2017 Jul;2017:1-10.

PMID:
28700190
16.

The future of prescription drug cost-sharing: real progress or dropped opportunity?

Fairman KA.

J Manag Care Pharm. 2008 Jan-Feb;14(1):70-82. No abstract available.

17.

The association of insurance type with costs of dispensed drugs.

Mott DA, Kreling DH.

Inquiry. 1998 Spring;35(1):23-35.

PMID:
9597015
18.

The FDA and prescription pancreatic enzyme product cost.

Gardner TB, Munson JC, Morden NE.

Am J Gastroenterol. 2014 May;109(5):624-5. doi: 10.1038/ajg.2013.430. No abstract available.

19.

Challenges to orphan drugs access in Eastern Europe: the case of Bulgaria.

Iskrov G, Miteva-Katrandzhieva T, Stefanov R.

Health Policy. 2012 Nov;108(1):10-8. doi: 10.1016/j.healthpol.2012.08.013. Epub 2012 Aug 29.

PMID:
22939047
20.

Forum discusses biosimilars, better biologicals.

Thompson CA.

Am J Health Syst Pharm. 2011 Dec 1;68(23):2210. doi: 10.2146/news110081. No abstract available.

PMID:
22095804

Supplemental Content

Support Center